Comprehensive medication guide to Buprenorphine/Naloxone including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With insurance, most patients pay $0 to $30 per month for generic Buprenorphine/Naloxone, though brand Suboxone may require prior authorization.
Estimated Cash Pricing
Without insurance, Buprenorphine/Naloxone costs $40 to $600 per month depending on whether you use a generic or brand-name formulation.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Buprenorphine/Naloxone is a prescription combination medication used to treat opioid use disorder (OUD). It is FDA-approved for opioid detoxification and long-term maintenance therapy, helping patients reduce cravings and withdrawal symptoms so they can focus on recovery.
The medication is available as a sublingual film (placed under the tongue), sublingual tablet, or buccal film (placed against the cheek). Brand names include Suboxone, Zubsolv, and Bunavail, and affordable generic versions are widely available.
![How to Find a Doctor Who Can Prescribe Buprenorphine/Naloxone Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2Fb90e6841a90ef2e0095ddbd589a5ab45040bf4f7-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![Why Is Buprenorphine/Naloxone So Hard to Find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F7b723976d2be73105e8c2f11cab491f45faafaf2-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors. As a partial agonist, it activates opioid receptors enough to reduce cravings and withdrawal symptoms but does not produce the full euphoric high of drugs like heroin, oxycodone, or fentanyl. This "ceiling effect" also lowers the risk of respiratory depression compared to full agonist opioids.
Naloxone is an opioid antagonist included in the formulation to deter misuse. When Buprenorphine/Naloxone is taken sublingually as directed, naloxone has minimal effect because it is poorly absorbed through the mouth. However, if someone attempts to inject the medication, the naloxone component blocks opioid receptors and can trigger immediate withdrawal symptoms.
2 mg/0.5 mg
sublingual film or tablet (commonly used during induction)
4 mg/1 mg
sublingual film or tablet
8 mg/2 mg
sublingual film or tablet (most commonly prescribed maintenance dose)
12 mg/3 mg
sublingual film
Zubsolv tablets
0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8.6 mg/2.1 mg, 11.4 mg/2.9 mg
Bunavail buccal film
2.1 mg/0.3 mg, 4.2 mg/0.7 mg, 6.3 mg/1 mg
Buprenorphine/Naloxone has a findability score of 45 out of 100, meaning it can be moderately difficult to locate in stock. Only about 58% of pharmacies regularly stock this medication. While there is no official national shortage as of early 2026, localized supply disruptions are common due to DEA ordering limits on controlled substances, pharmacy stocking decisions influenced by stigma around opioid use disorder treatment, and limited willingness among some pharmacies to carry Schedule III medications for OUD.
Patients in rural areas may face the greatest challenges finding Buprenorphine/Naloxone in stock. Using Medfinder can help you quickly locate pharmacies near you that currently have it available.
As of 2023, the X-waiver requirement was eliminated, meaning any healthcare provider with a DEA license can now prescribe Buprenorphine/Naloxone for opioid use disorder. Common prescribing specialties include:
Buprenorphine/Naloxone is also widely available through telehealth services, making it easier for patients to access treatment from home.
Yes, Buprenorphine/Naloxone is classified as a Schedule III controlled substance by the DEA. This means it has accepted medical use but carries a moderate potential for physical and psychological dependence. Because of its Schedule III classification, prescriptions can be called in or sent electronically to pharmacies, and refills are permitted (unlike Schedule II medications which require a new prescription each time).
The Schedule III classification also affects pharmacy stocking, as DEA ordering limits can contribute to localized supply issues.
Serious side effects (seek medical attention immediately):
Boxed Warning: Risk of serious harm or death from intravenous misuse. Life-threatening respiratory depression when combined with benzodiazepines or other CNS depressants. Keep out of reach of children — accidental ingestion can be fatal.
Know what you need? Skip the search.
Methadone
A full opioid agonist for OUD treatment, dispensed only through certified opioid treatment programs (OTPs). Highly effective but requires daily clinic visits initially.
Naltrexone (Vivitrol)
An opioid antagonist available as a monthly injection. Patients must be fully detoxed from opioids before starting. Has no abuse potential.
Sublocade
An extended-release buprenorphine monthly injection that eliminates the need for daily dosing. Requires initial stabilization on sublingual Buprenorphine/Naloxone.
Brixadi
A weekly or monthly subcutaneous buprenorphine injection approved in 2023 for OUD treatment.
Prefer Buprenorphine/Naloxone? We can find it.
Benzodiazepines
moderate(Xanax, Valium, Klonopin) — Risk of fatal respiratory depression
Other CNS depressants
moderateincluding alcohol, sedatives, and sleep aids
Full opioid agonists
moderate(oxycodone, hydrocodone, fentanyl) — May reduce efficacy or trigger precipitated withdrawal
CYP3A4 inhibitors
moderate(ketoconazole, ritonavir, itraconazole) — Can increase buprenorphine blood levels
CYP3A4 inducers
moderate(rifampin, carbamazepine, phenytoin) — Can decrease buprenorphine blood levels
SSRIs and SNRIs
moderateRisk of serotonin syndrome
MAO inhibitors
moderateMuscle relaxants
moderateSedating antihistamines
moderateBuprenorphine/Naloxone is a cornerstone medication for opioid use disorder treatment, supported by decades of research showing it reduces opioid cravings, prevents withdrawal, and significantly lowers the risk of overdose death. While it scores a 45 out of 100 on our findability scale due to localized stocking challenges, generic options are affordable — often $40 to $80 per month with a discount card — and insurance coverage is widely available.
If you're having trouble finding Buprenorphine/Naloxone in stock at your local pharmacy, Medfinder can help you search nearby pharmacies that currently have it available. Don't let a stocking issue delay your treatment.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini